

# **Case Study Competition – Final Round**


Track	Data Visualization	
College/University	BANARAS HINDU UNIVERSITY	
Software/tool used	PYTHON/POWERBI/EXCEL	


Student Name	Email ID	PG Course	Current semester/Year
SRIRAM RAVIKISHOR	sriramravikishor.bhu.comp@g mail.com	MSC STATISTICS AND COMPUTING	2 <sup>nd</sup> year
NALLI GEETA GAYATRI	geetagayatrinalli.bhu.stcomp @gmail.com	MSC STATISTICS AND COMPUTING	2 <sup>nd</sup> year
NAGARAJU K	nagaraju.bhu.stcomp@gmail.c om	MSC STATISTICS AND COMPUTING	2 <sup>nd</sup> year

#### • GUIDED BY


Shiva Prasad Jacob Mathew

## **Exploring Demographic characteristics by Treatments**







# TRTOIP OARM A OARM B OARM C S Scanned With SEX CamScanner



## **Exploring Baseline characteristics by Treatments**




#### count of treatment type by baseline weight



#### Count of treatment count by baseline height




# Overview of Treatment emergent Adverse Events



# AE during on \_ therapy by intensity


### GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS



#### NERVOUS SYSTEM DISORDERS



#### GASTROINTESTINAL DISORDERS




#### SKIN AND SUBCUTANEOUS TISSUE DISORDERS



#### CARDIAC DISORDERS



#### INFECTIONS AND INFESTATIONS



## RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS



#### psychiatric disorders



#### procedure complications



#### metabolism and nutrition disorders





# Distribution of days on study to adverse events



#### 8


# Distribution of BMI across visits






## Final result of the treatment

#### FINAL RESULT OF TREATMENT




10 Novo Nordisk®

## Final result of the treatment



#### FINAL RESULT OF THE TREATMENT



## **CONCLUSION:**

- We have used python and power BI tools to manipulate and explore the data.
- We used plots like barplot, histplot, distplot, BOX-plot, pie chart and Area chart for visualizing the data.
- We found that distribution of BMI across visits follows normal distribution shows there is not much variance in BMI across visits.
- We observed 24 kinds of adverse events occurred during the treatment.
- General disorder adverse event has occurred most with 24.52% among all adverse events followed by skin disorder adverse event with 23%.
- Reproductive system and breast disorders has highest average duration.
- Found severity count for every adverse event.
- We finally observed that 43% of the subjects have completed the treatment and remaining percentage of subjects have discontinued because of various reasons
- Like adverse events, physician decescion, death etc.
- The majority of the subjects who received the treatment of ARMA completed the treatment.

Novo Nordisk®